ImpediMed appoints Dr. Nicole Stout as Chief Clinical Innovation Officer
ImpediMed (ASX: IPD) has announced that Nicole L. Stout, DPT, CLT-LANA, FAPTA, will join as Chief Clinical Innovation Officer, effective 1 November 2026. The appointment is tied to the company’s SOZO Digital Health Platform, which Dr. Stout will help bring to more care settings.
Dr. Stout will lead clinical strategy, research, medical affairs and key opinion leader engagement, with a focus on accelerating adoption of the SOZO Digital Health Platform across care settings. For investors, the role is a senior clinical hire aimed at turning clinical evidence into adoption within health systems.
When big ASX news breaks, our subscribers know first
A 25-year cancer survivorship authority joins the team
Dr. Stout has spent more than 25 years helping oncology teams identify treatment-related complications early and intervene before they become disabling. Her record is paired with experience putting new care models into practice inside health systems.
Career credentials
Her background, as outlined by the company, includes:
- 25+ years in cancer rehabilitation and survivorship
- Most recent role as Senior Director of Survivorship and Wellness at the American Cancer Society, where she led a national portfolio of programs and initiatives addressing supportive care needs across the cancer continuum
- Earlier clinical, research and leadership roles at the West Virginia University Cancer Institute and the NIH Clinical Center
- Strategic initiatives involving the National Institutes of Health and the World Health Organization
- More than 100 peer-reviewed and invited articles on survivorship care delivery
Credentials of this kind may carry weight with oncology decision-makers, who influence purchasing of technology such as SOZO.
Evidence base for the Prospective Surveillance Model
Dr. Stout’s pioneering research helped establish the evidence base for the Prospective Surveillance Model (PSM). In simple terms, the approach pairs pretreatment baseline assessments with risk-stratified interval monitoring, then refers patients to supportive care when changes appear.
Risk-stratified monitoring means patients are checked at intervals matched to their level of risk. The aim is for care teams to address the physical and functional effects of cancer and its treatment throughout the care continuum.
She has designed and implemented surveillance pathways in health systems, resulting in shortened time to intervention for cancer treatment-related conditions and improved clinical operations and service-line performance. Because her work centres on surveillance, her expertise connects directly to the way SOZO is intended to be used.
Why SOZO is positioned for surveillance programs
The SOZO Digital Health Platform is already established in lymphedema assessment. The company points to two developments that add to that foundation:
- The National Accreditation Program for Breast Centers (NAPBC) Optimal Resources for Breast Care 2027 standards name bioimpedance spectroscopy (BIS) as a method that meets Standard 5.8, its new lymphedema assessment requirement.
- In August 2026, ImpediMed received FDA 510(k) clearance for sarcopenia risk assessment, enabling care teams to use the same scan to monitor muscle loss.
Together, according to the company, these give health systems a foundation for surveillance programs that extend across cancer types and treatment settings.
The sarcopenia risk assessment clearance matters because sarcopenia develops in roughly one in three breast cancer patients during chemotherapy, and SOZO draws the new indication from its existing muscle-mass indices without extra hardware.
The company also notes that in March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema.
Management commentary
Erik Anderson, Managing Director and Chief Executive Officer, pointed to Dr. Stout’s blend of research and practical delivery.
Erik Anderson, Managing Director and Chief Executive Officer
“Nicole brings a rare combination of scientific leadership and a proven ability to translate innovation into clinical practice…”
He added that she is joining to help drive SOZO in a defined direction.
Erik Anderson, Managing Director and Chief Executive Officer
“…bringing all of her experience to drive SOZO as a standard of care for cancer survivorship…”
Dr. Stout described her focus on practical delivery of surveillance.
Dr. Nicole Stout
“My career has focused on making prospective surveillance practical by connecting objective assessment with clinical workflows, timely intervention, and measurable outcomes…”
She also set out what she aims to help oncology teams achieve.
Dr. Nicole Stout
“…now is the time to bring together this platform along with my expertise in clinical evidence and implementation to help oncology teams adopt sustainable models of care in cancer survivorship programs.”
What happens next for ImpediMed investors
Two dated items follow from the announcement:
- Start date: Dr. Stout begins as Chief Clinical Innovation Officer on 1 November 2026, with responsibility for clinical strategy, research, medical affairs and key opinion leader engagement.
- Investor webinar: Dr. Stout will join the Q1 FY27 Results Investor Webinar scheduled for 9.00am on Friday 30 October 2026 to introduce herself and discuss why she believes SOZO can become the standard of care for cancer survivorship.
The company describes the connected digital health platform and the large, attractive cancer-related lymphoedema market as an opportunity for continued strong growth through its SaaS subscription-based business.
Get Healthcare News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to get real-time healthcare alerts the moment market-moving news breaks, ahead of the crowd.